Casdin Capital’s PMV Pharmaceuticals PMVP Stock Holding History

Casdin Capital’s Portfolio PMVP Stock Details PMVP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-300,000	Closed	-$4.28M	–	42
2022 Q2	$4.28M	Buy	+300,000	New	+$4.37M	0.36%	31

Other funds holding PMVP

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Casdin Capital's PMVP Position: Q3 2022 in Review

Casdin Capital sold out of PMV Pharmaceuticals (PMVP) in Q3 2022, closing a stake of 300,000 shares — an estimated $4.28M sold.

Casdin Capital first reported a position in PMVP in Q2 2022 and held it in 1 quarter. The position peaked at $4.28M in Q2 2022. 120 funds tracked by Wall St. Rank hold PMVP as of Q3 2022.

Casdin Capital reported no remaining PMV Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Casdin Capital sold 300,000 PMV Pharmaceuticals shares in Q3 2022, an estimated $4.28M.
Casdin Capital first reported a position in PMV Pharmaceuticals in Q2 2022 and held it in 1 quarter.
Casdin Capital's PMV Pharmaceuticals position peaked at $4.28M in Q2 2022.
120 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2022.

Based on Casdin Capital's 13F filing for Q3 2022, filed 14 Nov 2022.